FDA Archives - Page 78 of 220

2 minute read

Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline At 2023 ASCO Annual Meeting

April 26, 10:04 AM

Blueprint Medicines Corporation (NASDAQ:BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO)

BPMC

2 minute read

IN8bio Announces Oral Presentation Of New INB-200 Phase 1 Data In Glioblastoma To Be Presented At 2023 ASCO Annual Meeting

By Happy Mohamed

April 26, 10:04 AM

IN8bio, Inc. (NASDAQ:INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced an oral presentation at the upcoming 2023 American Society of Clinical

INAB

3 minute read

Novocure Announces Presentation Of Results Of The LUNAR Phase 3 Clinical Trial In Non-Small Cell Lung Cancer At 2023 American Society Of Clinical Oncology Annual Meeting

By Happy Mohamed

April 26, 10:03 AM

Novocure (NASDAQ:NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of Clinical

NVCR

2 minute read

Zentalis To Present Clinical Data In Ovarian Cancer Combining Azenosertib And Chemotherapy, Including Clinical Support For Cyclin E1 Expression As Predictive Marker For Clinical Benefit From Azenosertib At The 2023 ASCO Annual Meeting

By Happy Mohamed

April 26, 10:02 AM

Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with

ZNTL

3 minute read

Bolt Biotherapeutics To Present Clinical Data From Phase 1 Dose-Escalation Trial Of BDC-1001 in HER2-Expressing Tumors At 2023 ASCO Annual Meeting

By Happy Mohamed

April 26, 10:02 AM

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today announced that it will present a poster with clinical

BOLT

1 minute read

Galera To Present 1-Year Reductions In Cisplatin-Related Chronic Kidney Disease Data From ROMAN Trial At 2023 American Society Of Clinical Oncology Annual Meeting

By Happy Mohamed

April 26, 10:01 AM

Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform

GRTX

2 minute read

ContraFect Announces First Patient Dosed In The Phase 1b/2 Study Of Exebacase In Patients With Chronic Prosthetic Joint Infections Of The Knee

By Happy Mohamed

April 26, 9:02 AM

ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical

CFRX

4 minute read

Inhibrx Initiates A Registration-Enabling Trial Of INBRX-101 In AATD And Announces Lift Of Partial Clinical Hold On INBRX-109 DR5 Agonist Trials

By Happy Mohamed

April 26, 9:01 AM

Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has initiated a registration-enabling

INBX

3 minute read

FDA Accelerated Approval Of Tofersen Highlights Importance Of Blood Neurofilament Light Chain As Surrogate Endpoint In Neurology Therapeutic Trials

By Happy Mohamed

April 25, 11:56 PM

Blood-based measurement of neurofilament light chain (NfL) provides compelling evidence to support an accelerated drug approval by the FDA. The decision has positive implications for NfL blood testing as a key tool in

QTRX

9 minute read

New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept In Wet Age-Related Macular Degeneration And Diabetic Macular Edema

By Happy Mohamed

April 25, 3:02 PM

‒ Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration (AMD) and diabetic macular edema (DME) – ‒ More

RHHBY